ZOMETA® Works With Patients' Chemotherapy Regimens To Prevent Skeletal Related Events (SREs)
ZOMETA - Zoledronic AcidZOMETA - Zoledronic Acid Novartis Oncology
HomeZOMETA - International SiteZOMETA - US ResidentsZOMETA - Country Sites
ZOMETA - English ZOMETA - Deutsch ZOMETA - Espanol ZOMETA - Francais ZOMETA - Italiano
ZOMETA-Videos
Blue Arrow View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
ZOMETA European Summary of Product Characteristics
Blue Arrow For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics
 
ZOMETA Dosing & Administration ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)


Dose every 3 to 4 weeks ZOMETA with chemotherapy How to administer Ensuring renal safety Supplement for success References

ZOMETA® 4 mg every 3 to 4 weeks works with patients' chemotherapy regimens

  • ZOMETA does not require extra office visits when the patient is being treated with an every 2-week, 3-week, or 4-week chemotherapy regimen
  • According to US claims database research, the majority of patients with advanced cancer are treated with an every 3-week or 4-week regimen11
    • — 85% of patients with advanced prostate cancer
    • — 91% of patients with advanced breast cancer
    • — 93% of patients with multiple myeloma
    • — 95% of patients with advanced lung cancer